China Adds 119 New Drugs to NRDL after 51% Price Cuts

China has added 119 new therapies to its National Reimbursement Drug List after drugmakers from China and the rest of the world accepted price reductions of 51% to be included. Although the price cuts were painful, they were 10% less severe than last year. The negotiations took longer than expected. The additions to the NRDL include three PD-1 inhibitors from China biopharmas, bringing the total to four. PD-1 products from BeiGene , Jiangsu Hengrui Medicine and Shanghai Junshi Biosciences join an Innovent PD-1 checkpoint inhibitor, the first China-developed offering in the category. More details.... Share this with colleagues: // //